Skip to main content
. 2016 Oct;16(5):412–418. doi: 10.7861/clinmedicine.16-5-412

Fig 2.

Fig 2.

Investigation and management pathway for patients with potential or suspected glucocorticoid-CYP3A4 inhibitor interaction (expert opinion). *Depending on local assay. A&E = accident and emergency department; DMARD = disease-modifying antirheumatic drugs; HPA = hypothalamic-pituitary-adrenal; IA = intra-articular; IM = intra-muscular; SAI = secondary adrenal insuffi ciency; SST = short synacthen test.